Sort   by:  
 Page size 
ProteomicsBCAT1 Confers Resistance to EGFR TKIs through α-KG-dependent Epigenetic Regulation of the Glycolysis Pathway in NSCLC
Epidermal growth factor receptor (EGFR) mutations are leading oncogenic drivers in non-small cell lung cancer (NSCLC). Many third-generation EGFR tyrosine kinase inhibitors (TKIs) have been developed to target EGFR T790M and activating mutations. Osimertinib (AZD9291) was the first approved drug and...
ORGANISM(S): Homo Sapiens 
2023-07-14 | PXD043776 |
GenomicsAnalysis of the lncRNA-miRNA-mRNA network reveals a potential regulatory mechanism of EGFR-TKIs resistance in NSCLC
Analysis of the lncRNA-miRNA-mRNA network reveals a potential regulatory mechanism of EGFR-TKIs resistance in NSCLC
PRJNA796971 | ENA
GenomicsnCounter analysis of patients progressed to TKIs
nCounter analysis of patients progressed to TKIs
PRJNA986063 | ENA
GenomicsGenomic profiling of imatinib resistant and sensitive K562 cells to obtain insights into imatinib resistance
Chronic myeloid leukemia (CML) epitomizes successful targeted therapy, with 86% of patients in the chronic phase treated with tyrosine kinase inhibitors (TKIs) attaining remission. However, resistance to TKIs occurs during treatment, and patients with resistance to TKIs progress to the acute phase c...
ORGANISM(S): Homo sapiens 
2024-01-01 | E-MTAB-11896 | biostudies-arrayexpress
TranscriptomicsAnalysis of the lncRNA-miRNA-mRNA network reveals a potential regulatory mechanism of EGFR-TKIs resistance in NSCLC
In this study, to investigate the underlying molecular mechanisms of how EGFR-TKIs resistance occurs in NSCLC, we examined gene expression using microarray technology on gefitinib-resistant NSCLC cells to obtain differentially expressed (DE) lncRNAs and mRNAs. Then we carried out KEGG enrichment ana...
ORGANISM(S): Homo sapiens 
2022-01-14 | GSE193628 | GEO
TranscriptomicsGenomic profiling of immature hematopoietic cells to obtain insights into imatinib resistance
Chronic myeloid leukemia (CML) epitomizes successful targeted therapy, with 86% of patients in the chronic phase treated with tyrosine kinase inhibitors (TKIs) attaining remission. However, resistance to TKIs occurs during treatment, and patients with resistance to TKIs progress to the acute phase c...
ORGANISM(S): Homo sapiens 
2024-01-01 | E-MTAB-11899 | biostudies-arrayexpress
TranscriptomicsTranscription profiling by array of human wild type and gefitinib-resistant A431 cancer cells
A431 wild-type (wt) cancer cell line is sensitive to treatment with EGFR tyrosine kinase inhibitors (TKIs). By culturing it chronically under gefitinib, it eventually becomes resistant (A431_GR cell). We know of a few proteins involved in this mechanism of drug resistance, but a cDNA exprssion array...
ORGANISM(S): Homo sapiens 
2008-04-06 | E-GEOD-10696 | biostudies-arrayexpress
UnknownNovel agents and strategies for overcoming EGFR TKIs resistance.
Not available
S-EPMC3898214 | biostudies-literature
GenomicsActivation of the NF-κB/ALDH1A1 Signaling Promotes Non-Mutational Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer
Activation of the NF-κB/ALDH1A1 Signaling Promotes Non-Mutational Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer
PRJNA1433375 | ENA
UnknownHSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs.
Not available
S-EPMC7919131 | biostudies-literature
Sort   by:  
 Page size